A Phase 2 Clinical Trial Evaluating AMG 714 Treatment for Vitiligo
For a complete list of clinical trials in the USA, click here.
About Vitiligo and AMG 714
- Vitiligo is an autoimmune disorder in which some of your body’s immune cells, called T cells, attack melanocytes (the pigment producing cells in the skin). This leads to patches of skin depigmentation (loss of normal skin color). Scientists believe that specific T cells, called tissue resident memory T cells (Trm), are involved in the attack on melanocytes. Trm cells depend on the chemical signal IL-15. Therefore, scientists believe that interrupting the IL-15 signal might lead to a decrease in Trm cells, which might make vitiligo better.
- AMG 714 is an experimental drug that interferes with IL-15 and may stop the immune system’s attack on melanocytes and allow the melanocytes to produce normal color in the skin (repigmentation).
What do participants need to know?
- Eligible participants will be randomly assigned to one of two groups: One group will receive the study drug, AMG 714; the other group will receive an inactive substance called a placebo.
- This study is double-blinded, which means that during the study, neither you nor your study doctor will know who is receiving AMG 714 or placebo.
- The treatment period is 12 weeks long, consisting of 6 clinic visits with subcutaneous doses every 2 weeks
- The follow-up period is approximately 36 weeks, during which there are 5 clinic visits
- During the follow-up period, participants may require Narrowband Ultraviolet B light (nbUVB) phototherapy treatment for approximately 24 weeks which will be provided at no cost
- You will have a 2 out of 3 chance of receiving active study drug, and a 1 out of 3 chance of receiving placebo
You may be eligible to participate in the REVEAL study if you:
- Are between the ages of 18 and 75
- Have been diagnosed with vitiligo by a dermatologist
- Have a noticeable amount of vitiligo both on your face and on your body
- Are willing to stop other treatments for vitiligo
To learn more, contact the site(s) above, or visit the REVEAL website at: http://www.revealstudy.org
Study locations and Contacts
Henry Ford Health System, Detroit, MI (PI: Iltefat Hamzavi, MD)
Contact: Angie Parks-Miller
Tel: (313) 916-0426
Contact: Jennifer Creasor
Tel: (313) 916-0427
Northwell Health, Long Island (PI: George Han, MD)
Contact: Sabah Iqbal
Tufts Medical Center, Boston, MA (PI: Jeff Sobell, MD)
Contact: Nicole Dumont
Tel: (617) 636-7462
UC Irvine, Irvine, CA (PI: Anand Ganesan, MD)
UC Davis, Davis, CA (PI: Victor Huang, MD)
Tel: (916) 551-2636
University of Massachusetts (PI: Mehdi Rashighi, MD)
Contact: Rachel Wetstone
Tel: (774) 455-4758
Yale University, New Haven, CT (Brett King, MD)
Contact: Andrea DeClement
Tel: (203) 785-5182